Progeneer, a developer of next-generation immunomodulator (adjuvant), has announced on the 26th that it has secured strategic investment from HLB Biostep, a preclinical CRO company. Progeneer is currently developing cancer combination therapies targeting solid tumors and lymphoma cancer vaccines, based on its ProLNG immunomodulator (adjuvant) platform. Additionally, the company is expanding its business into the viral vaccine sector by leveraging the antiviral properties of ProLNG

https://www.wowtv.co.kr/NewsCenter/News/Read?articleId=A202402260192&t=NN